Abstract:Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder and affects millions of individuals globally. AD is associated with cognitive decline and memory loss that worsens with aging. A statistical report using U.S. data on AD estimates that approximately 6.9 million individuals suffer from AD, a number projected to surge to 13.8 million by 2060. Thus, there is a critical imperative to pinpoint and address AD and its hallmark tau protein aggregation early to prevent and manage its debilitating effects. Amyloid-β and tau proteins are primarily associated with the formation of plaques and neurofibril tangles in the brain. Current research efforts focus on degrading amyloid-β and tau or inhibiting their synthesis, particularly targeting APP processing and tau hyperphosphorylation, aiming to develop effective clinical interventions. However, navigating this intricate landscape requires ongoing studies and clinical trials to develop treatments that truly make a difference. Genome-wide association studies (GWASs) across various cohorts identified 40 loci and over 300 genes associated with AD. Despite this wealth of genetic data, much remains to be understood about the functions of these genes and their role in the disease process, prompting continued investigation. By delving deeper into these genetic associations, novel targets such as kinases, proteases, cytokines, and degradation pathways, offer new directions for drug discovery and therapeutic intervention in AD. This review delves into the intricate biological pathways disrupted in AD and identifies how genetic variations within these pathways could serve as potential targets for drug discovery and treatment strategies. Through a comprehensive understanding of the molecular underpinnings of AD, researchers aim to pave the way for more effective therapies that can alleviate the burden of this devastating disease.

Neuroprotective factors affect the progression of Alzheimer's disease

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

Gut Microbiota Mediates Neuroinflammation in Alzheimer’s Disease: Unraveling Key Factors and Mechanistic Insights

Epigenetic Modification and Its Role in Alzheimer's Disease

A multifactorial lens on risk factors promoting the progression of Alzheimer's disease

Advances In Recent Patent And Clinical Trial Drug Development For Alzheimer'S Disease

Single Nucleotide Polymorphism and Alzheimer¢s Disease

Progress in pathogenesis and treatment of Alzheimer's disease

The Epigenetics of Alzheimer’s Disease: Factors and Therapeutic Implications

The role of brain-derived neurotrophic factor and the neurotrophin receptor p75NTR in age-related brain atrophy and the transition to Alzheimer’s disease

Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease

Advances in Genetic and Molecular Understanding of Alzheimer's Disease

Etiological Insights and Degradation Strategies

Mechanisms of Alzheimer’s Disease Pathogenesis and Prevention: The Brain, Neural Pathology, N-methyl-D-aspartate Receptors, Tau Protein and Other Risk Factors

Novel Genetic Variants in TP37, PIK3R1, CALM1, and PLCG2 of the Neurotrophin Signaling Pathway Are Associated with the Progression from Mild Cognitive Impairment to Alzheimer's Disease

Novel Disease-Modifying Therapies for Alzheimer's Disease.

Advances in the Mechanism and Pharmacotherapies of Alzheimer's Disease

Advances in the Pathogenesis of Alzheimer’s Disease: Focusing on Tau-Mediated Neurodegeneration

Updates in Alzheimer's disease: from basic research to diagnosis and therapies

Neurotransmitters in Prevention and Treatment of Alzheimer's Disease

[Alzheimer's Disease: Advance in Researches on Beta-amyloid Protein].